Perrigo has won a US appeals court ruling on its generic version of Pepcid Complete. However, the company’s Prescription generics business saw a 15% drop in sales and a 28% decline in operating profit as the firm reported its 2018 results, ahead of plans to separate the Prescription unit from the company as it transitions to become a ‘self-care’ company.

Perrigo’s newly-appointed president and chief executive officer, Murray Kessler, has backed the planned ‘separation’of the firm’s ‘Rx’ Prescription US generics operation, but has also praised the business’ potential, albeit in the face of a disappointing financial third quarter.

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.